B-cell-specific signatures reveal novel immunophenotyping and therapeutic targets for hepatocellular carcinoma

Figure 7 Functional enrichment analysis of different risk score groups. A: Heatmap displays the expression levels of the top 50 differentially expressed genes across different risk score groups in hepatocellular carcinoma (HCC) samples; B: Volcano plot illustrates the differentially expressed genes across different risk score groups. Red indicates fold change > 2, false discovery rate (FDR) < 0.05; green indicates fold change < 2, FDR < 0.05; C: Bubble plot presents the Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis results across different risk score groups; D: Bubble plot demonstrates gene ontology (GO) enrichment analysis pathways and proportions across different risk score groups; E: Bubble plot exhibits GO enrichment analysis pathways, number of genes, and their statistical significance across different risk score groups; F: Gene set enrichment analysis (GSEA) analysis reveals the key pathways enriched in HCC patients with high risk scores; G: GSEA analysis unveils the key pathways enriched in HCC patients with low risk scores; H: Somatic mutation data analysis showcases the mutation rates of key genes in HCC patients with high risk scores; I: Somatic mutation data analysis displays the mutation rates of key genes in HCC patients with low risk scores; J: Survival analysis illustrates the prognosis of HCC patients in different tumor mutation burden groups; K: Survival analysis demonstrates the impact of tumor mutation burden combined with risk score groups on the prognosis of HCC patients. FC: Fold change; ECM: Extracellular matrix; HIF: Hypoxia-inducible factor; KEGG: Kyoto encyclopedia of genes and genomes.